Shire's 2015 results beat expectations

11 February 2016
shire-logo-big

Ireland-headquartered Shire (LSE: SHPL) posted fourth quarter 2015 non-generally accepted accounting principles (GAAP) earnings per share of $2.97, up 13%, on revenue up 9% to $1.72 billion, both beating analysts' consensus of $2.87 and $1.70 billion, respectively. The firm’s shares rose 2.75% to £36.66 following the announcement this morning.

For full-year 2015, Shire generated revenues of $6.4 billion, up 7% compared with 2014, or up 11% on a currency adjusted basis. EPS was 10% higher (+14% currency adjusted) at $11.68. Analysts had expected, on average, revenues of $6.31 billion and EPS of $11.40.

However net profits were down sharply at $1.3 billion from $3.4 billion in 2014, when Shire benefited from a $1.6 billion break-up fee, when AbbVie pulled out of its tax-inversion aimed takeover of Shire.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical